Capricor Therapeutics (CAPR) Insider Trading & Ownership $7.21 -0.20 (-2.70%) Closing price 04:00 PM EasternExtended Trading$7.33 +0.12 (+1.66%) As of 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Capricor Therapeutics (NASDAQ:CAPR) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage10.50%Number OfInsiders Buying(Last 3 Years)3Amount OfInsider Buying(Last 3 Years)$15.04MNumber OfInsiders Selling(Last 3 Years)1Amount OfInsider Selling(Last 3 Years)$12.18K Get CAPR Insider Trade Alerts Want to know when executives and insiders are buying or selling Capricor Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CAPR Insider Buying and Selling by Quarter Capricor Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails9/20/2024Shinyaku Co Ltd NipponMajor ShareholderBuy2,798,507$5.36$14,999,997.52 10/12/2023David B MusketDirectorBuy410$2.75$1,127.50 10/9/2023David B MusketDirectorBuy5,083$2.82$14,334.06 10/6/2023Paul Gisbert AuwaerterDirectorBuy5,000$2.84$14,200.00 10/4/2023David B MusketDirectorBuy2,500$2.90$7,250.00 3/28/2023Xavier AvatinsiderSell3,000$4.06$12,180.00 (Data available from 1/1/2013 forward) CAPR Insider Trading Activity - Frequently Asked Questions Who is on Capricor Therapeutics' Insider Roster? The list of insiders at Capricor Therapeutics includes David B Musket, Paul Gisbert Auwaerter, Shinyaku Co Ltd Nippon, and Xavier Avat. Learn more on insiders at CAPR. What percentage of Capricor Therapeutics stock is owned by insiders? 10.50% of Capricor Therapeutics stock is owned by insiders. Learn more on CAPR's insider holdings. Which Capricor Therapeutics insiders have been buying company stock? The following insiders have purchased CAPR shares in the last 24 months: David B Musket ($22,711.56), Paul Gisbert Auwaerter ($14,200.00), and Shinyaku Co Ltd Nippon ($14,999,997.52). How much insider buying is happening at Capricor Therapeutics? Insiders have purchased a total of 2,811,500 CAPR shares in the last 24 months for a total of $15,036,909.08 bought. Capricor Therapeutics Key ExecutivesFrank I. Litvack M.D. (Age 59)Independent Executive Chairman of the Board Linda Marban Ph.D. (Age 51)President, Chief Executive Officer, Director Anthony Bergmann (Age 32)Chief Financial Officer, Principal Accounting Officer Karen G. Krasney J.D. (Age 62)Executive Vice President, General Counsel Thomas Lyle Copmann Ph.D. (Age 61)Vice President - Regulatory Affairs and Drug Development Houman Hemmati M.D.Ph.D., Vice President - Medical & Clinical Development, New TherapiesLuis Rodriguez-Borlado Ph.D.Vice President - Regenerative TherapiesRachel Smith Ph.D. (Age 36)Vice President - Research & Development Deborah Ascheim M.D.Chief Medical OfficerJoshua A. Kazam (Age 40)Director More Insider Trading Tools from MarketBeat Related Companies LENZ Therapeutics Insider Ownership Amylyx Pharmaceuticals Insider Ownership Dianthus Therapeutics Insider Ownership Collegium Pharmaceutical Insider Ownership Enliven Therapeutics Insider Ownership Precigen Insider Ownership Nuvation Bio Insider Ownership WAVE Life Sciences Insider Ownership atai Life Sciences Insider Ownership Oric Pharmaceuticals Insider Ownership Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Top Insider Buys and Sells From September: Buy, Sell, or Hold?NuScale, Rocket Lab Face Heavy Insider Selling After Surges3 Small Caps That Insiders Are Buying $100 Million Buyback in Upwork Stock Follows a Strong Quarter Insiders Sell These High-Quality Stocks: Why Investors Shouldn’t This page (NASDAQ:CAPR) was last updated on 9/30/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBuy this stock tomorrowFamed futurist Eric Fry just unveiled his “Sell This, Buy That” strategy — including 7 free trade ideas like a...InvestorPlace | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capricor Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Capricor Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
